Skip to main content
Top
Published in:

Open Access 01-06-2025 | Multiple Sclerosis | Original Communication

Personalized therapy in multiple sclerosis: an Italian Delphi consensus

Authors: Claudio Gasperini, Diego Centonze, Antonella Conte, Paolo Gallo, Alessandra Lugaresi, Francesco Patti, Maria Trojano, Maria Pia Amato, Massimo Filippi

Published in: Journal of Neurology | Issue 6/2025

Login to get access

Abstract

Objective

The increasing availability of disease-modifying therapies (DMTs) may provide more personalized treatment options for multiple sclerosis (MS) based on various factors, including patients’ characteristics, prognostic indicators, comorbidities, and safety. In Italy, recent efforts focused on promoting interdisciplinary, patient-centered care and equitable access to optimized therapies, as reported in the 2023 Barometer of Multiple Sclerosis and Related Diseases from the Italian Multiple Sclerosis Association. A key challenge is ensuring equitable access to homogeneous and personalized therapeutic strategies.

Materials and methods

Using a Delphi methodology, a panel of Italian neurologists with expertise in MS evaluated consensus on specific aspects of MS treatments, including personalized therapy, patient involvement in decision-making, treatment flexibility, self-management of therapies, perception of treatment efficacy and safety and therapeutic sequence management.

Results

Of 166 votes, 116 statements reached consensus (68% positive, 2% negative), representing 70% of the total, whereas 50 (30%) highlighted areas of non-consensus. The findings emphasize the central role of neurologists, the importance of personalized therapy, the inclusion of patients in therapeutic choices to enhance adherence and quality of life, and managing both quality of life and caregiver burden. Most high-efficacy disease-modifying therapies (HE DMTs), like cladribine and anti-CD20 therapies, recognized for their efficacy and convenience of administration, received positive consensus, emphasizing their perceived value in individualized treatment approaches.

Conclusions

This research highlights best practices and provides a roadmap for improving patient outcomes through tailored, well-communicated therapeutic strategies.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Personalized therapy in multiple sclerosis: an Italian Delphi consensus
Authors
Claudio Gasperini
Diego Centonze
Antonella Conte
Paolo Gallo
Alessandra Lugaresi
Francesco Patti
Maria Trojano
Maria Pia Amato
Massimo Filippi
Publication date
01-06-2025

EAN 2025

Unlock your free and exclusive access to the latest news and expert interviews from the European Academy of Neurology's annual congress.

Read more

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest